Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBy the second week of Wegovy, most people are still on the 0.25 mg starting dose and are only beginning to notice any real shift in appetite. Side effects, if they appear, tend to peak in this window, then ease. That pattern is documented in the NHS medicines guide for semaglutide and reflects what the STEP 1 trial participants reported across their first few weeks. This is a POM — a prescription-only medicine — so your prescriber has already assessed whether it is clinically right for you. What follows is designed to help you read what your body is doing and feel more confident about what comes next.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
If you followed the prescribed schedule, your second injection came roughly a week after your first. That puts you still firmly in the 0.25 mg phase, which exists for one reason: to let your gut adjust to a new signal it has never received before. The appetite shift that many people are hoping for can be subtle at this stage, and that is completely expected. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks, the early weeks are about tolerability, not transformation.
Nausea is the most frequently reported experience in week two. It tends to arrive a few hours after injection and, for most people, fades within a day or two. Eating smaller meals, avoiding rich or fatty food, and staying well hydrated all help. Constipation is also common, not dramatic, but noticeable. Some people find the opposite: loose stools for a day or so. Both reflect the way semaglutide slows gastric emptying. If you want a broader picture of the full first month, the week one overview covers the baseline, and this week builds directly on it.
Fatigue and mild headache appear occasionally in week two, possibly linked to eating less than usual. If your appetite has already dropped (even modestly) make a conscious effort to eat enough protein and drink water through the day. These small choices matter more than they sound right now.
Most of what people experience in week two sits firmly in the normal category: low-level nausea, slightly altered hunger cues, perhaps a day of unusual tiredness. These do not require action beyond the practical steps above. They are your body recalibrating, not a sign that something has gone wrong.
A few things do warrant contact with your clinical team. Vomiting that stops you keeping fluids down for more than a day is one. Dehydration can become a real problem quickly when combined with reduced appetite, and your prescriber may advise pausing or adjusting your plan. Gallbladder-type pain (sharp, upper-right abdominal discomfort) should be reported. And the one sign to treat as urgent: severe stomach pain that does not ease and spreads towards your back. This pattern can indicate acute pancreatitis, which the MHRA highlighted as an infrequent but serious risk in a January 2026 Drug Safety Update on GLP-1 medicines. It is rare. Knowing about it is useful; worrying about it constantly is not. Call 999 or go to A&E if that specific combination of symptoms appears.
Injection-site reactions (a small raised area, mild redness, brief tenderness) are worth noting but not alarming. Rotating sites between your abdomen, thigh and upper arm with each weekly injection reduces them over time. If you have questions about what you're experiencing, our frequently asked questions cover the most common week-by-week concerns, and our aftercare team is available seven days a week.
Here is something our prescribers hear regularly: people in week two wondering whether the medicine is actually working. It almost certainly is, even if the scale has not moved yet. Semaglutide's appetite effect builds gradually as the dose increases over months. The 0.25 mg starting dose is the adjustment phase, think of it as your system learning a new resting state. The doses that carry the most clinical weight come later in the titration schedule, as your prescriber takes you through 0.5 mg, 1.0 mg, 1.7 mg and ultimately 2.4 mg over several months.
If you are curious how the picture tends to shift as time goes on, the guide to how long Wegovy takes to work sets out the realistic timeline across the full treatment course. If you would like a detailed day-by-day breakdown of this particular point in your journey, our guide to what to expect in your second week of Wegovy walks through the experience in more depth, and the companion overview of week two on Wegovy covers the same period from a slightly different angle, which some people find useful to read alongside it. Week five, when many people have completed their second dose step, often feels meaningfully different from week two, the week five overview is worth reading when you get there.
One honest thing worth saying: it is completely natural to feel impatient right now, or quietly uncertain whether this was the right call. That feeling is common in week two, and it usually shifts as the weeks move on and the effect becomes clearer. Most people find that patience in this early phase pays off. If you started treatment through a service other than nume and are now wondering about your options, or if you are still at the research stage, you can read more about Wegovy as a treatment or look at the broader range of weight-loss options we offer.
For anyone still deciding whether to start, Wegovy is a prescription-only medicine requiring a full clinical assessment before any treatment can be dispensed. If you would like our GPhC-registered prescribers to review your suitability, check your eligibility with a free consultation and we can take it from there.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.